Think About This : There is an inherent flaw in the way we analyse & decipher #covid19 #testing in #low #testing #markets like #India. For every 100 #covidー19 tests that we undertake #worldwide a #fraction of them is either a mandatory repeat testing for health workforce surveillance or a Pre surgical routine testing .
And this combined #fraction is estimated anywhere between 10%-12% of the overall test volume(could vary across a cross section of countries) . Such a percent looks smoothened when it comes to countries undertaking 20,000-60,000 per 100,000 testing .
The challenge when it comes to countries like #India , if we consider a peak of 1,500 testing per 100,000 , and apply this logic , one would realise that the “Active New Case “ detection per 100,000 is abysmally low. This gains even more critical attention when we have now begun to report – “Asymptomatic” as a dominant category .
Time we relooked at the #testing targets and rapidly built capabilities and scale .
Image : Not To Scale